DDInter166 DDInter1676
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Basiliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Basiliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Basiliximab may lead to a major life threatening interaction when taken with Upadacitinib
Basiliximab may lead to a major life threatening interaction when taken with Infliximab